CytoReason
CytoReason is a computational biology company based in Tel Aviv, Israel, founded in 2016. The company specializes in AI-driven disease modeling for the pharmaceutical and biotech industries. CytoReason develops proprietary computational models that simulate human diseases at a cellular level, bridging the gap between extensive molecular data and traditional analytical methods. The company's core offerings include computational disease models that integrate various molecular data types to map disease mechanisms. This technology supports target prioritization, biomarker discovery, combination therapy profiling, and clinical trial optimization, ultimately aiming to reduce costs and enhance drug approval success rates. CytoReason collaborates with top pharmaceutical companies, utilizing proprietary datasets to refine its models and adapt to new research areas. With a total funding of $20 million, CytoReason has attracted notable investors, including Pfizer and PICO Partners. The company continues to grow and expand its disease model library through ongoing collaborations, focusing on data-driven approaches to drug development.
Work at CytoReason in HR or recruiting? Claim this page
Headcount trend
CytoReason went from 127 employees in Oct 2024 to 116 in Sep 2026. Apr to Sep 2026: 2 people joined, 5 left.
Funding rounds
| Date | Round | Money raised | No. | Investors |
|---|---|---|---|---|
| Jul 2024 | Series B | $80M | 4 | |
| Sep 2022 | Funding | $20M | 1 | |
| Jun 2021 | Funding | $30M | – | – |
Org structure
Headcount by department
Peer reviews
Worked with someone at CytoReason?
Anonymous peer reviews on OffTheRecord
Similar companies
CytoReason FAQ
How many employees does CytoReason have?
CytoReason has about 116 employees, unchanged over the 3 months to Sep 2026.
What is CytoReason's revenue per employee?
CytoReason makes about $17K in revenue per employee, based on $2M annual revenue and 116 employees.
How much funding has CytoReason raised?
CytoReason has raised $130M in total funding; its latest round was Series B in Jul 2024.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.